pressure (hypertension), and muscle pain (myalgia). In December 2021, the United States Food and Drug Administration (FDA) granted nirmatrelvir/ritonavir
pressure (hypertension), and muscle pain (myalgia). In December 2021, the United States Food and Drug Administration (FDA) granted nirmatrelvir/ritonavir
Patients with mild to moderate symptoms who are in the risk groups can take nirmatrelvir/ritonavir (marketed as Paxlovid) or remdesivir, either of which reduces
moderate symptoms who are in the risk groups[needs update] can take nirmatrelvir/ritonavir (marketed as Paxlovid) or remdesivir, either of which reduces
December 2021, the Israeli Ministry of Health approved the use of Pfizer's Nirmatrelvir/ritonavir for treating COVID-19. The virus begun to rapidly spread after